Thyroid Cancer Biomarker Panel for NIFTP Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecular tests for thyroid nodules face challenges in distinguishing benign from malignant tumors, particularly with the introduction of the noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) subtype, leading to high false positive rates and unnecessary surgeries.
Innovation Solution
A quantitative RT-PCR based splice-variant-specific diagnostic gene panel is developed, utilizing markers such as HMGA2, PLAG1, KLK7, FNDC4, and CDH3 to differentiate between benign and malignant thyroid tumors, including the NIFTP subtype, with high sensitivity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA-based molecular tests (ThyroSeq, Afirma) are used for preoperative assessment of thyroid nodules, then the ability to detect malignant mutations is improved, but the specificity decreases due to prevalence of assessed mutations in benign thyroid lesions and inability to differentiate NIFTP from invasive FVPTC
Solution Approach 1:
The patent transitions from DNA-based mutation detection to RNA-based splice variant detection. This parameter change in the molecular target (from DNA to RNA) enables differentiation of NIFTP from invasive FVPTC, as splice variants are differentially expressed between these conditions while DNA mutations are present in both. The RNA-based approach uses quantitative RT-PCR to measure expression levels of specific splice variants, providing superior diagnostic specificity.
2Reliability
If current molecular tests report NIFTP as positive or suspicious for malignant disease, then sensitivity for detecting potential malignancy is improved, but false positive rate increases leading to unnecessary surgeries
Solution Approach 1:
The patent segments the diagnosis into distinct categories by detecting specific splice variant expression patterns. Instead of a single positive/negative result, the panel identifies distinct expression profiles for benign thyroid lesions, NIFTP, and invasive FVPTC. This segmentation allows precise classification, reducing false positives by correctly identifying NIFTP as a separate entity with its own characteristic splice variant signature.
3Measurement precision
If visual microscopic diagnosis (FNA cytopathology) is used for thyroid nodule assessment, then the ability to detect obvious malignant features is improved, but indeterminate cytology results occur in up to 30% of cases
Solution Approach 1:
The patent introduces RNA splice variant expression analysis as an intermediary between FNA cytology and final diagnosis. For indeterminate cytology cases, the molecular panel provides additional diagnostic information that bridges the gap between ambiguous visual assessment and definitive malignancy determination. The splice variant profile acts as a mediator that resolves uncertainty in Bethesda III, IV, and V categories.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The panel achieves an 85% ability to distinguish malignant from benign tumors with 90% specificity and 75% sensitivity, and effectively differentiates indolent NIFTP from invasive FVPTC with 85% specificity and 60% sensitivity, reducing unnecessary surgeries and guiding appropriate surgical management.
Implementation Method 1
measuring expression, in a sample obtained from the patient, by real-time quantitative polymerase chain reaction (RT-qPCR) of at least three splice variant markers
Data Source
AI summary
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods directed to a thyroid cancer-specific biomarker panel. In a specific embodiment, a methods for identifying at thyroid tumor/nodule as benign or malignant comprises the steps of (a) measuring expression, in a sample obtained from the patient, by real-time quantitative polymerase chain reaction (RT-PCR) of at least three splice variant markers of a panel comprising high mobility group AT-hook 2 (HMGA2), transcript variant 1; PLAG1 zine finger (PLAG1), transcript variant 1; kallikrein related peptidase 7 (KLK7), transcript variant 1; fibronectin type III domain containing 4 (FNDC4); and cadherin 3 (CDH3), transcript variant 1; and (b) identifying the tumor as benign or malignant based on the measured expression levels of the panel of splice variant markers as compared to a control.